文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

极高危前列腺癌盆腔淋巴结剂量递增IMRT联合前列腺同步大分割推量的长期结局:前瞻性II期临床试验

Long-Term Outcomes of Dose-Escalated Pelvic Lymph Node Intensity-Modulated Radiation Therapy (IMRT) With a Simultaneous Hypofractionated Boost to the Prostate for Very High-Risk Adenocarcinoma of the Prostate: A Prospective Phase II Clinical Trial.
PubMed 文献 · Pract Radiat Oncol · 2021-04-10

中位随访6.4年,生化失败无生存率80.2%,前列腺癌特异生存率95.2%,5年无远处转移生存率96%,毒性可耐受。

要点

  • 盆腔淋巴结56 Gy/28次联合前列腺同步推量70 Gy/28次方案可行且耐受良好。
  • 中位随访6.4年,生化失败无生存率80.2%,前列腺癌特异生存率95.2%。
  • 5年无远处转移生存率96%,在极高危人群中结果令人鼓舞。

核心结论

  • 在单臂小样本前瞻性可行性研究中,盆腔淋巴结放疗剂量递增安全、可行且耐受性看似良好。
  • 在以NCCN极高危为主的人群中,无进展生存率结果高度令人鼓舞。

研究设计与样本

  • 入组条件包括计算淋巴结风险至少25%、Karnofsky体能状态评分≥70、无M1病变证据。
  • 盆腔淋巴结接受56 Gy/28次,前列腺同步整合推量至总剂量70 Gy/28次,采用IMRT。
  • 急性和晚期毒性采用CTCAE v4.0在每个随访点前瞻性收集。

主要发现

  • 患者中位年龄70岁(57-83),治疗前PSA中位11.5 ng/mL(3.23-111.5),T分期为T2c(T1c-T3b),Gleason评分9(6-9)。
  • CTCAE v4.0任何1级或2级泌尿生殖毒性和胃肠道毒性发生率分别为55%和44%。
  • 报告1例急性3级泌尿生殖毒性和胃肠道毒性,均与方案治疗无关。
  • 中位随访6.4年,生化失败无生存率80.2%,生化无进展生存均值8.3年(95%CI 7.2-9.4)。
  • 前列腺癌特异生存率95.2%,均值8.7年(95%CI 8.0-9.4),5年无远处转移生存率96%,中位数未达到。

关键数值与推荐

  • 盆腔淋巴结放疗剂量56 Gy/28次,前列腺同步整合推量总剂量70 Gy/28次。
  • 入组计算淋巴结风险至少25%,Karnofsky体能状态评分≥70,无M1病变。
  • 毒性分级采用CTCAE v4.0。

临床怎么用

  • 对于极高危前列腺癌患者,可考虑盆腔淋巴结剂量递增联合前列腺同步推量的IMRT方案。
  • 治疗中需按CTCAE v4.0前瞻性监测急性和晚期泌尿生殖及胃肠道毒性。

局限性

  • 中位随访6.4年,部分生存指标中位数未达到。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There remains limited data as to the feasibility, safety, and efficacy of higher doses of elective radiation therapy to the pelvic lymph nodes in men with high-risk prostate cancer. We conducted a phase II study to evaluate moderate dose escalation to the pelvic lymph nodes using a simultaneous integrated boost to the prostate. METHODS AND MATERIALS: Patients were eligible with biopsy-proven adenocarcinoma of the prostate, a calculated lymph node risk of at least 25%, Karnofsky performance scale ≥70, and no evidence of M1 disease. Acute and late toxicity were prospectively collected at each follow-up using Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0). The pelvic lymph nodes were treated to a dose of 56 Gy over 28 fractions with a simultaneous integrated boost to the prostate to a total dose of 70 Gy over 28 fractions using intensity-modulated radiation therapy. RESULTS: Thirty patients were prospectively enrolled from October 2010 to August 2014. Median patient age was 70 years (57-83), pretreatment prostate-specific antigen was 11.5 ng/mL (3.23-111.5), T stage was T2c (T1c-T3b), and Gleason score was 9 (6-9). CTCAE v4.0 rate of any grade 1 or 2 genitourinary and gastrointestinal toxicity were 55% and 44%, respectively, and there was 1 reported acute grade 3 genitourinary and gastrointestinal toxicity, both unrelated to protocol therapy. With a median follow-up of 6.4 years, the biochemical failure free survival rate was 80.2%, and mean biochemical progression free survival was 8.3 years (95% confidence interval [CI], 7.2-9.4). The prostate cancer specific survival was 95.2%, and mean prostate cancer specific survival was 8.7 years (95% CI, 8.0-9.4). Five-year distant metastases free survival was 96%. Medians were not reached. CONCLUSIONS: In this single arm, small, prospective feasibility study, nodal radiation therapy dose escalation was safe, feasible, and seemingly well tolerated. Rates of progression free survival are highly encouraging in this population of predominately National Comprehensive Cancer Network very high-risk patients.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Hall WA, Bedi M, Kilari D, et al. Long-Term Outcomes of Dose-Escalated Pelvic Lymph Node Intensity-Modulated Radiation Therapy (IMRT) With a Simultaneous Hypofractionated Boost to the Prostate for Very High-Risk Adenocarcinoma of the Prostate: A Prospective Phase II Clinical Trial. Pract Radiat Oncol. 2021. PMID: 33848618. doi:10.1016/j.prro.2021.03.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。